Mesenchymal/Stromal Gene Expression Signature Relates to Basal-Like Breast Cancers, Identifies Bone Metastasis and Predicts Resistance to Therapies
Figure 4
A17-signatures are enriched in basal-like breast tumors.
Module map analysis of Van the Vijver's (a) and Wang's (b) cohort indicated that A17-signatures were enriched in ER-negative human breast cancers. ‘Intrinsic subtypes’ of breast cancers with different clinical outcomes were identified on the Van de Vijver's cohort based on the clusterization of the most differentially expressed genes (c). Module map analysis using these subtypes as experimental groups demonstrated that all A17 signatures were significantly enriched in the basal-like subtype (d).